Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04754737 · ClinicalTrials.gov registry record · NA

Antibiotic Usage Prior to OnabotulinumtoxinA Injection

A NA study of Overactive Bladder and UTI, sponsored by Benaroya Research Institute.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT04754737: Recruiting NA study of Overactive Bladder and UTI, sponsored by Benaroya Research Institute.

NCT04754737 is a NA study of Overactive Bladder and UTI that is actively recruiting participants, run by Benaroya Research Institute. The registered enrollment target is 200 participants, roughly in line with the 203-participant average among 46 other Overactive Bladder trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04754737, a NA study of Overactive Bladder and UTI, is actively recruiting participants, sponsored by Benaroya Research Institute.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

Intradetrusor injection of onabotulinumtoxinA, which is performed through a cystoscopic procedure, has been demonstrated to be efficacious in the treatment of both neurogenic and non-neurogenic overactive bladder (OAB), and is FDA approved as a treatment for overactive bladder. Intradetrusor of onabotulinumtoxinA is currently standard of care of patients with OAB who have persistent OAB symptoms despite behavioral therapies and oral medication treatments for OAB. As one of the main adverse events associated with intradetrusor injection of onabotulinumtoxinA is UTI, and published guidelines for cystoscopic procedures with manipulation recommend the use of prophylactic antibiotics, a single dose of prophylactic antibiotic is administered prior to this procedure. However, these recommendations are primarily based on data from randomized controlled trials (RCTs) involving antimicrobial prophylaxis during transurethral resection of the prostate. A previously published prospective study demonstrated that the rate of post-procedural UTI did not differ amongst patients with neurogenic bladder who did not receive prophylactic antibiotics and were asymptomatic for UTI, regardless of whether they had sterile urine cultures or asymptomatic bacteriuria, suggesting that patients who are not symptomatic for UTI may not require antibiotic prophylaxis prior to intradetrusor onabotulinumtoxinA injection. Studies have reported that up to 50% of antibiotic usage is inappropriate, leading to unnecessary exposure of patients to potential complications of antibiotic therapy, including Clostridium difficile infection which can cause recurrent diarrhea that may progress to sepsis and death, increasing antibiotic resistances, as well as dermal/allergic and gastro-intestinal manifestations. Therefore, in an effort to optimize antibiotic use, the investigators propose a prospective, randomized study to formally evaluate the differences in UTI frequency in subjects who have a negative urinalysi

Primary Outcome

the number of symptomatic UTIs which occur within the 14 day period after cystoscopic intradetrusor injection of onabotulinumtoxinA

Interventions

  • OTHER No antibiotic
  • OTHER Prophylactic antibiotic
  • PROCEDURE cystoscopic injection of onabotulinumtoxinA

Study Locations (1)

New York

  • Stony Brook Medicine - Stony Brook

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2021-03-23
Est. Completion 2026-12
Phase NA
Benaroya Research Institute

28 total trials

What NCT04754737 shows while recruiting

NCT04754737 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 203-participant average among 46 other Overactive Bladder trials with a reported enrollment target.

The record links to 4 conditions, with Overactive Bladder appearing as the primary indexed condition, and to 3 interventions - of which No antibiotic is the first listed.

NCT04754737 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04754737 about?

NCT04754737 is a clinical study titled "Antibiotic Usage Prior to OnabotulinumtoxinA Injection". Intradetrusor injection of onabotulinumtoxinA, which is performed through a cystoscopic procedure, has been demonstrated to be efficacious in the treatment of both neurogenic and non-neurogenic overactive bladder (OAB), and is FDA approved as a treatment for overactive bladder. Intradetrusor of onab...

What is the current status of trial NCT04754737?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2021-03-23. Estimated completion is 2026-12.

What conditions does trial NCT04754737 study?

This clinical trial studies the following conditions: Overactive Bladder, UTI, Antibiotic Stewardship, Onabotulinumtoxin A.

What interventions are being tested in trial NCT04754737?

The interventions under investigation include: No antibiotic (OTHER), Prophylactic antibiotic (OTHER), cystoscopic injection of onabotulinumtoxinA (PROCEDURE).

Who is sponsoring clinical trial NCT04754737?

This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04754737 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Overactive Bladder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04754737's enrollment target sits among peer trials

200 13th of 46 higher than 33 of 46 other Overactive Bladder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04754737, the US trial registry maintained by the National Library of Medicine. NCT04754737 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.